Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Castle BiosciencesCSTL +4.67%81 EV-to-OCF is 14.67 as of Aug. 02, 2026, which is 179% above its 10-year median of 5.26. GuruFocus rates CSTL with a GF Score™ of 81/100 and a GF Value™ of $29.40 (Fairly Valued). The stock has 4 warning signs investors should review. Among 213 Medical Diagnostics & Research companies, Castle Biosciences ranks worse than 67.14% on this metric.
EV-to-OCF is calculated as enterprise value divided by its cash flow from operations. As of today, Castle Biosciences's Enterprise Value is $625.2 Mil.
Castle Biosciences's Cash Flow from Operations for the trailing twelve months (TTM) ended in Jun. 2026 was $42.6 Mil. Therefore, Castle Biosciences's EV-to-OCF for today is 14.67.
The historical rank and industry rank for Castle Biosciences's EV-to-OCF or its related term are showing as below:
CSTL'
s EV-to-OCF Range Over the Past 10 Years
Min: -604.58 Med: 5.26 Max: 219.44
Current: 14.67
During the past 9 years, the highest EV-to-OCF of Castle Biosciences was 219.44. The lowest was -604.58. And the median was 5.26.
CSTL's EV-to-OCF is ranked worse than 67.14% of 213
companies
in the Medical Diagnostics & Research industry
Industry Median: 6.26
vs CSTL: 14.67
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Castle Biosciences's PE Ratio (TTM) for today is calculated as:
Castle Biosciences's share price for today is $28.00.
Castle Biosciences's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.660.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Cash Flow from Operations is an important financial metric because it represents the cash generated from operating activities at a company's disposal. Companies with a low EV-to-OCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Castle Biosciences EV-to-OCF Related Terms
Castle Biosciences EV-to-OCF Historical Data
* Premium members only.
The historical data trend for Castle Biosciences's EV-to-OCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Diagnostics & Research subindustry, Castle Biosciences's EV-to-OCF, along with its competitors' market caps and EV-to-OCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Castle Biosciences EV-to-OCF vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Castle Biosciences's EV-to-OCF distribution charts can be found below:
* The bar in red indicates where Castle Biosciences's EV-to-OCF falls into.
Castle Biosciences's current Enterprise Value is $625.2 Mil.
Castle Biosciences's Cash Flow from Operations for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $42.6 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Castle Biosciences (CSTL) has a EV-to-OCF of 14.67 as of Aug. 02, 2026. This is 179% above median its historical median of 5.26. According to the industry distribution chart, Castle Biosciences ranks #143 out of 213 companies in the Medical Diagnostics & Research industry, placing it in the top 67.1%.
Is Castle Biosciences' EV-to-OCF too high?
Castle Biosciences' current EV-to-OCF of 14.67 is 179% above median its 10-year median of 5.26. The Medical Diagnostics & Research industry median EV-to-OCF is 6.26. Castle Biosciences' value of 14.67 is 134.3% above this industry median. Based on the distribution chart, Castle Biosciences ranks #143 out of 213 companies in the Medical Diagnostics & Research industry, which is below the industry midpoint. Overall, Castle Biosciences has a GF Score™ of 81/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Castle Biosciences' EV-to-OCF compare to OPK and FLGT?
According to the Medical Diagnostics & Research industry distribution chart, Castle Biosciences ranks #143 out of 213 companies for EV-to-OCF. This places Castle Biosciences in the lower half of its industry. The industry median EV-to-OCF is 6.26. Castle Biosciences' value of 14.67 is 134.3% above this benchmark. While the company's 10-year median is 5.26 vs. the industry median of 6.26, Castle Biosciences has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-OCF for a Medical Diagnostics & Research company?
The median EV-to-OCF among Medical Diagnostics & Research companies is 6.26, based on 213 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-OCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-OCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Castle Biosciences's current EV-to-OCF of 14.67 is 134.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-OCF mean?
A high EV-to-OCF can signal that a stock is expensive relative to its fundamentals. For the Medical Diagnostics & Research industry, the median EV-to-OCF is 6.26 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Castle Biosciences's current EV-to-OCF is 14.67, which is 179% above median its own 10-year median of 5.26. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Castle Biosciences stock overvalued right now?
Based on GuruFocus' analysis, Castle Biosciences (CSTL) is currently considered Fairly Valued. The stock's GF Value™ is $29.40, compared to a current price of $28.00 — trading 4.8% below its estimated fair value. The current EV-to-OCF is 14.67, which is 179% above median its 10-year median of 5.26 and 134.3% above the Medical Diagnostics & Research industry median of 6.26. Castle Biosciences' overall GF Score™ is 81/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-OCF calculated?
EV-to-OCF is calculated from a company's financial statements. For Castle Biosciences (CSTL), the current EV-to-OCF is 14.67 as of Aug. 02, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Castle Biosciences (CSTL) Overvalued in 2026?
Based on GuruFocus' analysis, Castle Biosciences stock appears to be undervalued.
The current stock price of $28.00 is trading 4.8% below its estimated GF Value™ of $29.40.
GuruFocus considers Castle Biosciences to be Fairly Valued.
Key valuation signals for CSTL:
EV-to-OCF: 14.67 (179% above median its 10-year median of 5.26)
GF Value™: $29.40 vs. price of $28.00 (4.8% below fair value)
Industry Position: 134.3% above the Medical Diagnostics & Research median (#143 of 213)
No single metric tells the full story. See the CSTL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Castle Biosciences Inc is a molecular diagnostics company. The group provides test solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus (BE), and uveal melanoma. The product portfolio of the company includes DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test; DecisionDx-SCC, a risk stratification test for cutaneous squamous cell carcinoma; MyPath Melanoma, a diagnostic GEP test for use in patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a test to predict future development of progression of high-grade dysplasia and/or esophageal cancer. The company derives revenues through the delivery of test reports for its molecular diagnostic tests.
81GF Score
Get the complete analysis for CSTL
EV-to-OCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CSTL has been successfully added to your 
